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More than 750,000 cases of severe sepsis are 
diagnosed each year in the United States alone 
(for review see reference 1). The incidence is 
predicted to increase by 1.5% per year, owing 
to aging of the population and the wider use of 
immunosuppressive agents and invasive pro-
cedures (2). It is widely believed that further 
gains in sepsis therapy will depend on the 
  successful targeting of the host response. Thus 
far, eff  orts to block one or another component 
of the infl  ammatory or coagulation pathways 
have had little impact on survival. Of the many 
agents and drugs that have been tested, only 
two have demonstrated effi     cacy in phase 3 
clinical trials: mouse monoclonal antibody to 
human TNF-α and human recombinant acti-
vated protein C (3, 4). However, despite these 
interventions, mortality rates remain high at 
25–30%. Clearly, future advances in therapy 
will be contingent upon an improved under-
standing of sepsis pathophysiology.
Vascular endothelial growth factor (VEGF)/
vascular permeability factor was fi  rst identifi  ed 
and characterized as a potent stimulator of 
  endothelial permeability (5). VEGF was sub-
sequently reported to promote proliferation, 
migration, and survival of endothelial cells (6). 
VEGF (also termed VEGF-A) is a member of a 
growing family of related proteins that include 
VEGF-B, -C, -D, and placental growth factor 
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Sepsis, the systemic infl  ammatory response to infection, is a leading cause of morbidity and 
mortality. The mechanisms of sepsis pathophysiology remain obscure but are likely to 
involve a complex interplay between mediators of the infl  ammatory and coagulation path-
ways. An improved understanding of these mechanisms should provide an important foun-
dation for developing novel therapies. In this study, we show that sepsis is associated with 
a time-dependent increase in circulating levels of vascular endothelial growth factor (VEGF) 
and placental growth factor (PlGF) in animal and human models of sepsis. Adenovirus-
mediated overexpression of soluble Flt-1 (sFlt-1) in a mouse model of endotoxemia at-
tenuated the rise in VEGF and PlGF levels and blocked the effect of endotoxemia on cardiac 
function, vascular permeability, and mortality. Similarly, in a cecal ligation puncture (CLP) 
model, adenovirus–sFlt-1 protected against cardiac dysfunction and mortality. When 
administered in a therapeutic regimen beginning 1 h after the onset of endotoxemia or 
CLP, sFlt peptide resulted in marked improvement in cardiac physiology and survival. Sys-
temic administration of antibodies against the transmembrane receptor Flk-1 but not Flt-1 
protected against sepsis mortality. Adenovirus-mediated overexpression of VEGF but not 
PlGF exacerbated the lipopolysaccharide-mediated toxic effects. Together, these data 
support a pathophysiological role for VEGF in mediating the sepsis phenotype.
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(PlGF; for review see reference 7). VEGF binds to two trans-
membrane receptors, namely Flt-1 and Flk- 1, whereas PlGF 
binds to Flt-1 alone. Within the vessel wall, Flk-1 is selec-
tively expressed in endothelium. Flt-1 is present on both 
  endothelial cells and monocytes.
In addition to its role in promoting endothelial permea-
bility and proliferation, VEGF may contribute to infl  amma-
tion and coagulation. For example, under in vitro conditions, 
VEGF induces the expression of cell adhesion molecules 
(E-selectin, intercellular adhesion molecule 1 [ICAM-1], and 
vascular cell adhesion molecule 1 [VCAM-1]) in endothelial 
cells and promotes the adhesion of leukocytes (8, 9). 
  Moreover, VEGF signaling up-regulates tissue factor mRNA, 
protein, and procoagulant activity (10). These proinfl  amma-
tory/procoagulant eff  ects of VEGF are mediated, at least in 
part, by the activation of NF-κB, Egr-1, and NFAT tran-
scription factors. VEGF has been implicated as a pathophysi-
ological mediator in several human disease states, including 
rheumatoid arthritis, cancer, and infl  ammatory bowel disease 
(11–13). Recently, two independent studies reported an as-
sociation between human severe sepsis/septic shock and ele-
vated circulating levels of VEGF (14, 15). We designed this 
study to test the hypothesis that VEGF plays a pathogenic 
role in mediating the sepsis phenotype.
Figure 1.  Circulating levels of VEGF and PlGF in mouse and human 
models of sepsis. (a) The levels of IL-6 (plasma), TNF-α (serum), PlGF 
(plasma), and VEGF (plasma) in LPS-injected mice at the time points indi-
cated; CTRL, control normal saline-injected mice. (b) Same as in a but in a 
CLP mouse model; sham, sham-operated control mice. (c) PlGF and VEGF 
levels in a mouse pneumonia model at 6 and 24 h. (d) PlGF and VEGF 
levels in a human endotoxemia model at the time points indicated. 
Subjects were administered LPS or saline (placebo). (e) Plasma PlGF and 
VEGF levels in randomly chosen patients with severe sepsis plotted 
against time in the intensive care unit (ICU). Each line represents an indi-
vidual patient (P). Mouse data are expressed as means ± SD (a and c) or 
as means ± SEM (b) of three independent experiments. Human data from 
the endotoxemia model are expressed as means ± SEM. *, P < 0.05; 
**, P < 0.01; ***, P < 0.0001.JEM VOL. 203, June 12, 2006  1449
ARTICLE
RESULTS
Circulating levels of VEGF and PlGF in animal 
and human models of sepsis
To confi  rm the association between sepsis and circulating 
VEGFs, we assayed plasma levels of VEGF (and the related 
growth factor PlGF) in both mouse and human models of 
  infection. As shown in Fig. 1 a, i.p. administration of LPS in 
mice resulted in a time-dependent increase in plasma VEGF 
and PlGF concentrations, with peak levels (477 and 4311 
pg/ml, respectively) occurring at 24 h. In contrast, circulat-
ing levels of IL-6 and TNF-α were maximal at the earliest 
time point measured (6 h). In a cecal ligation puncture (CLP) 
model of sepsis, peak levels of VEGF (137.26 pg/ml) and 
PlGF (71.25 pg/ml) occurred at 24 and 12 h, respectively 
(Fig. 1 b). In a mouse model of Escherichia coli pneumonia, 
plasma VEGF levels were not signifi  cantly altered (Fig. 1 c 
[1]), whereas PlGF levels were increased (23.01 pg/ml) at 6 h 
(Fig. 1 c [2]). In human subjects, the systemic administration 
of LPS resulted in elevated circulating levels of VEGF and 
PlGF (Fig. 1 d and Table S1, available at http://www.jem.
org/cgi/content/full/jem.20060375/DC1), with peak levels 
(70 and 23.5 pg/ml, respectively) occurring at 4 h in contrast 
to TNF-α and IL-6, which peaked at 1.5 and 2.5 h, respec-
tively (not depicted). Plasma levels of VEGF and PlGF were 
measured in 10 patients with severe sepsis and 10 healthy 
volunteers. At study entry, VEGF levels in the patients 
(mean and SD = 46.49 ± 46.17 pg/ml) were signifi  cantly 
higher than in the healthy volunteers (mean and SD = 3.83 ± 
3.16 pg/ml; P = 0.009). Similarly, PlGF levels in the patients 
at study entry (mean and SD = 13.52 ± 14.55 pg/ml) were 
signifi  cantly higher compared with healthy volunteers (mean 
and SD = 0.18 ± 0.58 pg/ml; P = 0.009). In most cases 
(8/10), the VEGF and PlGF levels remained elevated during 
their intensive care unit (ICU) stay (in some cases, up to 29 d). 
Figure 3.  Effect of sFlt-1 overexpression on circulating levels of 
sFlt, VEGF, and PlGF in a mouse model of endotoxemia. Mice were 
injected with adenovirus overexpressing GFP (CTRL-ad) or sFlt-1 (sFlt-ad). 
3 d later, the animals were administered saline (control) or LPS i.p. 
Blood samples were taken 24 h later and assayed for plasma levels of 
sFlt-1, free VEGF, and free PlGF. Data are expressed as means ± SD 
(error bars) of three independent experiments. *, P < 0.05; **, P < 0.01; 
***, P < 0.0001.
Figure 2.  VEGF and PlGF protein levels in a mouse model of endo-
toxemia. Results of ELISA for VEGF (top) and PlGF (bottom) in 
tissues from mice injected with or without LPS at the time points indi-
cated. *, P < 0.05; **, P < 0.01; ***, P < 0.0001. Error bars represent SD.1450  VEGF AND SEPSIS | Yano et al.
The maximum VEGF and PlGF levels were 221 and 96 pg/ml, 
respectively (Fig. 1 e).
To determine the source of elevated growth factor con-
centrations, VEGF and PlGF levels were assayed in various 
tissues using ELISA. Systemic administration of LPS in mice 
resulted in increased VEGF protein levels at 6 h in the liver 
(3.8-fold), kidney (1.9-fold), and heart (3.7-fold) but de-
creased levels in the brain, lung, and spleen (Fig. 2). PlGF 
protein was increased in all tissues examined, including the 
brain (4.8-fold), lung (7.1-fold), heart (71.8-fold), liver (35.2-
fold), kidney (28.5-fold), and spleen (28.4-fold; Fig. 2). There 
were no diff  erences in VEGF protein in the serum compared 
with plasma of LPS-treated or control mice, arguing against 
an important contribution of platelets to the plasma VEGF 
levels in endotoxemia (not depicted). Based on the aforemen-
tioned fi  ndings, we conclude that sepsis is associated with in-
creased expression and circulating levels of VEGF and PlGF.
Effect of sFlt-1 on endotoxemia-mediated induction 
of circulating VEGF and PlGF levels
To determine whether increased levels of VEGF and/or 
PlGF are important determinants of sepsis pathophysiology, 
mice were injected i.v. with adenovirus-overexpressing solu-
ble Flt-1 (sFlt-1) or GFP (control) before treatment with LPS. 
sFlt-1 is a natural splice variant of the cell surface receptor 
Flt-1 that binds to free VEGF-A, VEGF-B, and PlGF, thus 
blocking their interaction with cell surface receptors (16). 
Previous studies have shown that Ad–sFlt-1 (adenovirus–
sFlt-1) transduces liver hepatocytes in vivo and results in high 
circulating levels of sFlt-1 for up to 2 wk after injection 
Figure 4.  Effect of sFlt-1 overexpression on cardiac function in 
mouse models of sepsis. Mice were injected with adenovirus over-
expressing GFP (CTRL-ad; C) or sFlt-1 (sFlt-ad; S) in a–c, f, and g. 3 d later, 
the animals were administered saline (control) or LPS i.p. or were sub-
jected to CLP. Alternatively, mice were injected i.v. with PBS (C) or sFlt-1 
peptide (S) 1 h after LPS injection or CLP procedure (d, e, h, and i). An 
echocardiogram and electrocardiogram were performed 24 h after saline 
or LPS injections or 26 h after CLP. (a) Representative M modes and two-
dimensional images (insets) from an echocardiogram in an endo-
toxemia model. (b and d) Quantitative analysis of the fractional 
shortenings (FS) from an echocardiogram in an endotoxemia model. 
(f and h) Heart rate (HR) measurements on an electrocardiogram in an 
endotoxemia model. (c and e) Quantitative analysis of the fractional 
shortenings from an echocardiogram in a CLP model. (g and i) Heart rate 
measurements on an electrocardiogram in a CLP model. Analysis of vari-
ance was used for statistic analysis. Error bars represent SD. *, P < 0.05; 
**, P < 0.01; ***, P < 0.0001.JEM VOL. 203, June 12, 2006  1451
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(17, 18). As shown in Fig. 3, Ad–sFlt-1–treated mice 
  displayed elevated levels of sFlt-1 in the serum compared 
with Ad-GFP–treated animals. Importantly, Ad–sFlt-1 sig-
nifi  cantly inhibited LPS-mediated induction of free VEGF 
(P < 0.01) and PlGF (P < 0.05), whereas control adenovirus 
had no such eff  ect. Interestingly, in control animals, LPS in-
creased circulating levels of endogenous sFlt-1 (from 159.62 
to 1,585.40 pg/ml) and further increased total sFLT-1 in 
Ad–sFlt-1–treated animals (Fig. 3).
Effect of sFlt-1 on endotoxemia-mediated cardiac 
dysfunction and barrier dysfunction
Systemic administration of LPS or CLP in mice resulted in 
a marked depression of cardiac function (Fig. 4), as indicated 
by reduced fractional shortening (Fig. 4, b–e) and heart rate 
(Fig. 4, f–i) on echocardiography, and was associated with 
PR interval prolongation on an electrocardiogram (not 
depicted). These eff  ects were completely blocked by adeno-
virus-mediated overexpression of sFlt-1 (Fig. 4, b and f) but 
not GFP (control) or PBS (control) injection. Similar results 
were demonstrated in the CLP model (Fig. 4, c and g). LPS 
administration resulted in an organ-specifi  c loss of barrier 
function, with increased extravasation of Evans blue dye in 
the lungs, liver, and kidney but not in the brain, heart, or 
spleen (Fig. 5).  Overexpression of sFlt-1 completely blocked 
LPS-induced vascular leak in the liver and lung but only par-
tially inhibited the eff  ect of LPS on kidney permeability.
Effect of sFlt-1 on endotoxemia-mediated changes 
in mRNA expression of infl  ammatory 
and coagulation mediators
Exogenous sFlt-1 had no eff  ect on the initial 6-h peak of 
plasma cytokines induced during endotoxemia (Fig. 6). 
However, cytokine levels fell more rapidly in animals that 
had received Ad–sFlt-1 compared with control adenovirus. 
Ad–sFlt-1 signifi  cantly blunted LPS-mediated induction of 
TNF-α, IL-1β, IL-6, and D-dimers at 12 and/or 24 h 
(P < 0.05 for TNF-α and D-dimers at 12 h; P < 0.01 for 
IL-1β and IL-6 at 12 h and D-dimers at 24 h; P < 0.0001 for 
IL-6 at 24 h; Fig. 6, a–f). LPS administration in triple mutant 
mice that were null for IL-1RI and the two TNF-α receptors 
(TNFRs), TNFR1 and TNFR2, resulted in a signifi  cantly 
lower induction of VEGF (P < 0.05) and PlGF (P < 0.01) 
compared with wild-type controls at 24 h (Fig. 6, g–i). 
  Together, these fi  ndings suggest that VEGF and PlGF lie 
downstream of commonly implicated sepsis-induced cytokines.
Endotoxemia in mice was associated with increased 
mRNA expression of infl   ammatory and procoagulant 
  molecules (Fig. 7 A and Table S2, available at http://www.
jem.org/cgi/content/full/jem.20060375/DC1). As a negative 
control, VE-cadherin mRNA levels did not increase in any 
tissue examined (not depicted). In immunofl  uorescent stud-
ies, most of these infl   ammatory mediators were localized 
primarily in the endothelium (Fig. 7 B). In the heart, E-
  selectin, P-selectin, ICAM-1, VCAM-1, and Cox-2 were 
induced in small venules. ICAM-1 and VCAM-1 were also 
increased in capillary endothelium. PAI-1 was induced in 
capillaries alone. In the brain, all of the aforementioned 
  mediators were induced in the endothelium of venules but 
not capillaries. In the lung, E-selectin, P-selectin, ICAM-1, 
VCAM-1, and Cox-2 were increased in venular endothe-
lium. ICAM-1 and PAI-1 were increased in lung paren-
chyma. The immunohistochemical analyses demonstrated 
that the endothelial expression of these activation markers 
during endotoxemia was abrogated by the administration of 
sFlt-1 (Fig. 7 B).
To gain further insights into the mechanisms by which 
VEGF mediates sepsis morbidity and mortality, human 
Figure 5.  Effect of sFlt-1 overexpression on vascular permeability 
in a mouse model of endotoxemia. Mice were injected with adenovirus 
overexpressing GFP (CTRL-ad) or sFlt-1 (sFlt-ad). 3 d later, the animals 
were administered saline (control) or LPS i.p. 24 h later, the animals were 
injected i.v. with 0.1 ml of 1% Evans blue dye. After 40 min, the mice were 
perfused, and the brain (Br), lung (Lu), heart (H), liver (Li), kidney (Ki), and 
spleen (Sp) were harvested and incubated in formamide for 3 d to 
elute Evans blue dye. (left) Whole mount photomicrographs of organs. In 
each group, the left-most specimen is from control untreated mice, the 
middle specimen is from control adenovirus-treated endotoxemic mice, 
and the right specimen is from Ad–sFlt-1–treated endotoxemic mice 
(in the case of the kidney, two specimens are shown for each condition). 
(right) Quantitation of Evans blue extravasation (OD at 620 nm). Error 
bars represent SD. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.1452  VEGF AND SEPSIS | Yano et al.
umbilical vein endothelial cells (HUVECs) were incubated 
for 4 h with TNF-α, VEGF, and PlGF either alone or in 
combination. VEGF but not PlGF induced the expres-
sion of several genes, including VCAM-1 (9.3-fold), Cox-2 
(2.77-fold), and tissue factor (16.37-fold; Fig. 8). Endothelial 
cells treated with 0.1 ng/ml TNF-α alone demonstrated a 
29.35-fold increase in VCAM-1, a 2.13-fold increase in tis-
sue factor, and no change in Cox-2 mRNA levels. In con-
trast, 0.1 ng/ml TNF-α plus 100 ng/ml VEGF resulted in 
a signifi  cantly increased expression of VCAM-1, Cox-2, and 
tissue factor over and above the eff  ects of VEGF alone (P < 
0.01). These data suggest that VEGF sensitizes endothelial 
cells to low concentrations of TNF-α.
Effect of sFlt-1 and anti-VEGF receptor antibodies 
on sepsis mortality
Survival studies were performed in 20 mg/kg LPS-treated 
mice overexpressing GFP (control), VEGF, PlGF, or sFlt 
(Fig. 9 a). In the control group, 13/24 (54.2%) mice died 
from endotoxemia. sFlt-1 resulted in a signifi  cant reduction 
in mortality (2/24 animals died; P < 0.0008). Overexpres-
sion of VEGF (mean plasma levels of 5.08 ng/ml) resulted in 
a marked increase in LPS sensitivity (100% mortality), whereas 
overexpression of PlGF (mean plasma levels of 28.23 ng/ml) 
had no such eff  ect. sFlt-1 also improved survival in the CLP 
model of sepsis (Fig. 9 b). A total of 4/15 (27%) mice over-
expressing sFlt-1 died from CLP-induced sepsis compared 
Figure 6.  Effect of sFlt-1 overexpression on circulating cytokine 
levels and D-dimers in a mouse model of endotoxemia. (a–f) Mice 
were injected with adenovirus overexpressing GFP (CTRL-ad) or sFlt-1 
(sFlt-ad). 3 d later, the animals were administered saline (control) or LPS 
i.p. Serum or plasma levels of TNF-α, IL-1α, IL-1β, IL-6, sFlt-1, and 
D-dimer were measured at 6, 12, and 24 h. (g–i) Circulating levels of 
VEGF and IL-6 levels in triple mutant mice (IL-1−/−, TNFR1−/−, and 
TNFR2−/−) with LPS-induced endotoxemia. Plasma levels of VEGF, PlGF, 
and IL-6 in LPS-injected wild-type (WT) or triple mutant (TM) mice 24 h 
after i.p. injection of saline (control) or LPS. Error bars represent SD. 
*, P < 0.05; **, P < 0.01; ***, P < 0.0001.JEM VOL. 203, June 12, 2006  1453
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with 12/16 (75%) in the GFP-expressing control group (P = 
0.0063; Fig. 9 b). To further verify a primary role for VEGF, 
animals were pretreated with neutralizing antibodies against 
Flt-1 or Flk-1. In these experiments, anti–Flk-1 antibodies 
but not anti–Flt-1 antibodies reduced mortality in the mouse 
endotoxemia model (Fig. 9, c and d, respectively). Together, 
these fi  ndings suggest that VEGF-A is a critical determinant 
of the sepsis phenotype.
Therapeutic effect of sFlt-1 peptide on sepsis morbidity 
and mortality
To determine whether VEGF inhibition after the onset of 
sepsis results in improved outcome, mice were injected i.v. 
with 1 μg of human recombinant sFlt-1 peptide or an equal 
volume of PBS (control) every 3 h (four doses) beginning 
1 h after LPS administration or CLP procedure. sFlt-1 peptide 
completely blocked the eff  ects of LPS or CLP on fractional 
shortening (Fig. 4, d and e) and heart rate (Fig. 4, h and i). 
In survival studies, recombinant sFlt-1 improved survival in 
both endotoxemia and CLP models of sepsis. Mortality in 
LPS was reduced from 80 to 20% (P = 0.0091; Fig. 10 a), 
whereas CLP-mediated mortality was decreased from 83.3 to 
25% (P = 0.0061; Fig. 10 a). 
DISCUSSION
Despite decades of intense research, severe sepsis continues to 
be associated with an unacceptably high rate of mortality. It 
has been estimated that 500–1,000 patients die every day 
from this condition in the United States (2). An important 
goal is to identify novel therapeutic targets. However, further 
advances in therapy will be critically dependent on an im-
proved understanding of sepsis pathophysiology.
Using several diff  erent animal and human models, we 
have demonstrated that sepsis is associated with increased cir-
culating levels of VEGF and PlGF. Levels were highest in 
endotoxemia models, intermediate in CLP, and lowest in 
pneumonia. Importantly, the fi  ndings were confi  rmed in hu-
man models of endotoxemia and severe sepsis. In all cases, 
the induction of VEGF and PlGF levels occurred at a later 
time point compared with TNF-α, IL-1, and IL-6. sFlt-1 
blocked free VEGF and PlGF but had no eff  ect on the early 
increase of TNF-α, IL-1β, and IL-6. Moreover, triple mu-
tant mice that lack the ability to respond to IL-1 and TNF-α 
did not demonstrate LPS-mediated increases in VEGF and 
PlGF levels. Together, these fi  ndings strongly support the 
notion that VEGF and PlGF are late markers of sepsis and lie 
downstream of early response cytokines.
The administration of sFlt-1 attenuated LPS- and CLP-
mediated morbidity and mortality. Although sFlt-1 binds 
both VEGF and PlGF, several fi  ndings point to the primary 
importance of VEGF in mediating sepsis pathophysiology. 
First, PlGF concentrations were lower than circulating VEGF 
concentrations in human sepsis. Second, PlGF binds to Flt-1 
at a lower affi   nity than VEGF. Third, VEGF but not PlGF 
sensitized endothelial cells to the eff  ects of low TNF-α con-
centrations. Fourth, the overexpression of VEGF but not 
PlGF resulted in a marked increase in LPS sensitivity (100% 
mortality). Finally, and most importantly, antibodies against 
Flk-1 but not Flt-1 attenuated sepsis mortality.
All organs examined displayed increased levels of PlGF 
protein, whereas the heart, liver, and kidney were the major 
sources of VEGF induction. The fi  nding that VEGF levels 
were similar in serum and plasma (both in control and LPS-
treated mice) argues against a substantial contribution of 
platelets to the circulating pool of VEGF. The mechanisms 
underlying the induction of VEGF and PlGF remain be de-
termined. Although hypoxia is known to induce the expres-
sion of both growth factors, hypoxemia is not a universal 
fi  nding in mouse and human models of sepsis. Previous stud-
ies have shown that infl  ammatory mediators, including IL-1, 
IL-6, and Cox, may increase the mRNA expression of VEGF 
in various cell types (19–21). Under in vitro conditions, 
VEGF and glucose have been shown to induce PlGF mRNA 
and protein levels in endothelial cells (22). Thus, it is possible 
that the cytokine storm associated with sepsis contributes to 
the increase in VEGF and PlGF levels.
The observation that VEGF sensitizes endothelial cells to 
the eff  ects of low TNF-α concentrations suggests that the 
high VEGF levels observed in sepsis may serve to accentuate 
the activation phenotype. In addition, it is well established 
that VEGF induces endothelial permeability, an eff  ect that 
may contribute to the morbidity and mortality in sepsis. 
However, the precise mechanisms by which VEGF contrib-
utes to disease progression will require ongoing studies, 
  including the generation of lineage-specifi  c  conditional 
knockouts of VEGF receptors and/or the specifi  c/selective 
attenuation of one or another VEGF eff  ects.
The fi  nding that endotoxemia is associated with increased 
circulating levels of sFlt-1 is novel. Previous studies have 
demonstrated that circulating levels of sFlt-1 are increased in 
the third trimester of pregnancy and are abnormally elevated 
in patients with preeclampsia (18). These latter changes are 
associated with a reduction in circulating free VEGF and 
PlGF. Interestingly, TNF-α has been shown to induce the 
release of sFlt-1 from normal placental villous explants (23). 
Together, these data suggest that sepsis-associated changes 
in circulating sFlt-1 may represent an endogenous com-
pensatory anti-infl  ammatory mechanism.
In summary, our data support an association between sepsis 
and increased circulating levels of VEGF, PlGF, and sFlt-1. 
More importantly, the results suggest a pathophysiological role 
for VEGF in mediating the sepsis phenotype. Further studies 
are required to determine the diagnostic and/or prognostic 
value of these markers as well as the therapeutic potential of 
anti-VEGF strategies in patients with the sepsis syndrome.
MATERIALS AND METHODS
Mouse models of endotoxemia, CLP, and pneumonia. All animal 
studies were performed in accordance with guidelines established by the 
Beth Israel Deaconess Medical Center Animal Care and Use Committee or 
the Harvard Medical Area Standing Committee on Animals. LPS injections, 
CLP, and pneumonia models were performed in male 8-wk-old C57BL/6 
(22–24-g body weight). For the endotoxemia model, mice were i.p. injected 1454  VEGF AND SEPSIS | Yano et al.
Figure 7.  Effect of sFlt-1 overexpression on tissue mRNA/protein 
levels of infl  ammatory and hemostatic markers in a mouse model of 
endotoxemia. (a) Results of quantitative TaqMan analyses (mRNA copy 
number per 106 copies of 18S) of E-selectin, P-selectin, ICAM-1, VCAM-1,
Cox-2, and PAI-1 in the heart, brain, and lung of mice overexpressing 
GFP (C) or sFlt-1 (S) 24 h after i.p. injection with (LPS+) or without 
LPS (LPS−). Error bars represent SD of triplicate PCR reactions using 
pooled cDNA from three mice in each treatment group. The results are JEM VOL. 203, June 12, 2006  1455
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with normal saline (control) or LPS (18- mg/kg weight) from E. coli sero-
type 0111:B4 (Sigma-Aldrich). Where indicated, LPS was administered to 
triple mutant mice that were null for TNFR1, TNFR2, and the type I IL-1 
receptor or wild-type controls on a matched C57BL/6 × 129/Sv back-
ground. Triple mutant mice were maintained in a full barrier facility under 
specifi  c pathogen-free conditions (24). CLP was performed as previously 
described with minor modifi  cations (25). In brief, mice were anesthetized 
with isofl  uorane. After shaving the abdomen, a 2-cm midline incision was 
created under aseptic conditions to expose the cecum and adjoining intes-
tine. Approximately 25–30% of the cecum was ligated distal to the ileo-cecal 
valve with a 4–0 vicryl suture and punctured with a 21-gauge needle. The 
cecum was then gently squeezed to extrude a small amount of feces to ensure 
patency of the perforation sites and was returned to the peritoneal cavity. 
Mice received 1 ml of saline i.p. for fl  uid resuscitation at the time of closure 
and 0.1 mg/kg buprenorphine s.c. every 12 h to minimize distress. For the 
pneumonia model, mice were anesthetized by i.m. injection of 100 mg/kg 
ketamine hydrochloride, 5 mg/kg acepromazine maleate, and 0.1 mg/kg atro-
pine. The trachea was surgically exposed, and E. coli (strain 19138; American 
Type Culture Collection) were intratracheally instilled at 106 CFU/mouse 
via angiocatheter through the trachea to the left bronchus. After 6 or 24 h, 
mice were killed by halothane inhalation.
Human models of endotoxemia and sepsis. The human endotoxemia 
study was approved by the Institutional Review Board for the Protection of 
Human Subjects at the Beth Israel Deaconess Medical Center. In brief, after 
informed consent, the subjects underwent comprehensive screening and 
were included if they had no current or past history of psychiatric, neuro-
logical, immune, cardiovascular, or sleep disorders; no history of drug de-
pendence/abuse, including cigarette smoking during the last 6 mo; normal 
blood chemistry (complete and diff  erential blood counts, T cell subsets, glu-
cose, creatinine, sodium, potassium, and thyroid-stimulating hormone); and 
negative blood and urine toxicology. Subjects received an i.v. injection of 
either placebo or a host-response challenge with 2 ng/kg E. coli endotoxin 
(O:113; Lot EC-5). The human sepsis study was approved by the Research 
Ethics Board of the Hamilton Health Sciences (Henderson General Hospi-
tal). Patients with severe sepsis were identifi  ed in the ICUs of the Henderson 
General Hospital, St. Joseph’s Healthcare, and Hamilton General Hospital 
using the inclusion and exclusion criteria as previously described (26). Pa-
tients who received Xigris were excluded from the analysis. Baseline charac-
teristics of the patients were collected, including demographic information, 
acute physiology and chronic health evaluation (APACHE II) admission 
scores, multiple organ dysfunction scores, comorbidities, organ function, site 
and type of infection, and hematologic tests (Table S3, available at http://
www.jem.org/cgi/content/full/jem/20060375/DC1).
Measurement of cytokine levels in plasma, serum, or tissue lysates. 
TNF-α and IL-1 were measured in serum. IL-6, VEGF, and PlGF were mea-
sured in plasma. To isolate plasma from mice, blood samples were collected by 
heart puncture into heparinized tubes, centrifuged, and the supernatant was 
saved as plasma. To obtain mouse serum, blood samples were incubated over-
night at 4°C, centrifuged, and the supernatant was saved as serum. In the hu-
man endotoxemia study, blood samples were drawn at regular intervals in 
Figure 8.  Effect of VEGF and PlGF on the cytokine responsiveness 
of primary human endothelial cells. Results of quantitative TaqMan 
analyses (mRNA copy number per 106 copies of 18S) of VCAM-1 (a and d), 
Cox-2 (b and d), tissue factor (c and d), E-selectin (d), P-selectin (d), 
ICMA-1 (d), and PAI-1 (d) in serum-starved HUVECs treated for 4 h in the 
absence (CTRL; control) or presence of TNF-α, VEGF, and PlGF alone or in 
combination. (a–c) Data are expressed as means ± SD (error bars) of 
three independent experiments. **, P < 0.05; ***, P < 0.0001.
representative of two independent experiments. (b) Immunofl  uorescent 
studies of E-selectin, P-selectin, ICAM-1, vWF, Cox-2, and PAI-1 in the 
heart, brain, and lung of mice overexpressing GFP (CTL) or sFlt-1 24 h 
after i.p. injection with or without LPS. Serial sections were stained for 
vWF or CD31 to colocalize in endothelium. Bars, 50 μm.1456  VEGF AND SEPSIS | Yano et al.
EDTA tubes and set on ice for 5 min before centrifuging at 2,600 g, and 
plasma was pipetted into aliquots and stored at −80°C until subsequent as-
say. In patients with severe sepsis, blood was collected within 24 h of meet-
ing the defi  nition of severe sepsis. Blood was collected daily for the fi  rst 7 d 
and once a week thereafter for the duration of the patients’ stay in the ICU. 
9 ml venous blood was drawn via indwelling catheters from the patients. As 
controls, 9 ml venous blood was drawn via venipuncture from healthy adult 
volunteers. For each patient or volunteer, 4.5 ml of the collected blood was 
immediately transferred to 15 ml polypropylene tubes containing 0.5 ml 
of 0.105 M buffered trisodium citrate, pH 5.4, and the remaining 4.5 ml 
was transferred into 15-ml polypropylene tubes containing 0.5 ml of 0.105 
M buff  ered trisodium citrate, pH 5.4, and 100 μl of 1 M benzamidine HCl 
(20 mM benzamidine fi  nal). The blood was spun at 1,500 g for 10 min at 
20°C, and the plasma was stored as aliquots at –80°C. To prepare mouse or-
gan tissue lysates, mice were perfused with PBS containing 2 mM EDTA. 
Organs were removed and snap frozen in liquid nitrogen. Frozen tissues 
were homogenized in lysate buff  er containing 50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, and 0.05% protease inhibitor cocktail (Sigma-Aldrich) and 
were centrifuged to obtain the supernatant (tissue lysate). Mouse sFlt-1, 
VEGF, TNF-α, IL-6, IL-1α, and IL-1β were assayed using the Quantikine 
ELISA kit (R&D Systems). Mouse D-dimer was measured using Assera-
chrom DI-D, an enzyme immunoassay of D-dimer (Diagnostica Stago). Hu-
man plasma PlGF and VEGF-A were measured using human PlGF and 
VEGF Quantikine ELISA kits (R&D Systems).
Adenovirus-mediated overexpression of sFlt, VEGF, and PlGF. 
Mice were injected i.v. with adenovirus overexpressing GFP (2 × 108 pfu of 
control), 108 pfu of mouse sFlt-1, 2 × 108 pfu of mouse VEGF-A (isoform 
120), or 2 × 108 pfu of mouse PlGF-2. The construction of these viruses has 
been described previously (17, 18, 27). The dose of Ad–sFlt-1, Ad-VEGF, 
and Ad-PlGF was titrated to achieve plasma levels of  10–25 ng/ml. Com-
mercial Quantakine ELISA kits (R&D Systems) that measure mouse sFlt-1, 
VEGF, and PlGF were used to assay circulating levels of these cytokines 
from mouse plasma.
Antibody administration. 16 h before LPS administration, mice were in-
jected i.p. with an injection of 800 μg of anti–mouse Flk-1 antibody (DC101), 
1,200 μg of anti–mouse Flt-1 antibody (MF-1), or control PBS. Both antibodies 
were provided by D.J. Hicklin (ImClone Systems, Inc., New York, NY).
sFlt-1 peptide administration. Mice were injected i.v. with 1 μg of hu-
man recombinant sFlt-1 domain D1-3 (Cell Sciences, Inc.) or an equal vol-
ume of PBS (control) every 3 h for 12 h, beginning 1 h after LPS 
administration or CLP.
Cardiac physiological analysis. Echocardiographic examination of mice 
was performed as previously described (28, 29). In brief, mice were anesthe-
tized with i.p. injection of 50 mg/kg ketamine HCl and 10 mg/kg xylazine. 
A sector scanner (Sonos 1500; Hewlett-Packard) equipped with a 12-MHz 
transducer was used to record two-dimensionally guided M-mode tracings 
to assess left ventricle wall thickness, left ventricle dimensions, and fractional 
shortening. Electrocardiogram recordings were acquired on anesthetized 
mice with a multichannel amplifi  er and were converted to digital signals for 
analysis (PowerLab system; ADInstruments).
Figure 9.  Survival studies in mouse models of sepsis. (a) Survival 
curves for mice overexpressing GFP (CTRL-as), sFlt-1 (sFlt-ad), PlGF (PlGF-
ad), and VEGF (VEGF-ad) and injected i.p. with LPS. Circulating VEGF, 
PlGF, and sFlt-1 at 24 h after LPS injection was 5.08 ± 1.41 ng/ml, 
28.23 ± 5.84 pg/ml, and 20.64 ± 5.20 ng/ml, respectively. (b) Survival 
curves for mice overexpressing GFP (CTRL-as) or sFlt-1 (sFlt-ad) and sub-
jected to CLP. (c and d) Survival curves for endotoxemic mice pretreated 
with i.p. injection of antibodies against Flk-1 (c) or Flt-1 (d).JEM VOL. 203, June 12, 2006  1457
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Permeability assay. Mice were anesthetized by i.p. injection of 0.5 ml 
avertin. 100 μl of 1% Evans blue dye in PBS was injected into the tail 
vein. 40 min later, mice were perfused via heart puncture with PBS con-
taining 2 mM EDTA for 20 min. Organs (brain, heart, lung, liver, kid-
ney, and spleen) were harvested and incubated in formamide for 3 d to 
elute Evans blue dye. OD of formamide solution was measured using a 
620-nm wavelength.
Tissue RNA isolation and quantitative TaqMan PCR analysis. Tis-
sue RNA was isolated using TRIzol (Invitrogen) and the RNA mini prepa-
ration kit (QIAGEN). For quantitative real-time PCR, total RNA was 
prepared using the RNeasy RNA extraction kit with DNase I treatment ac-
cording to the manufacturer’s instructions (QIAGEN). To generate cDNA, 
100 ng of total RNA from each of triplicate samples was mixed and con-
verted into cDNA using random primers and Superscript III reverse tran-
scriptase (Invitrogen). All cDNA samples were aliquoted and stored at 
−80°C. Primers were designed using the Primer Express oligo design soft-
ware (Applied BioSystems) and synthesized by Integrated DNA Technologies. 
All primer sets (Table S4, available at http://www.jem.org/cgi/content/
full/jem.20060375/DC1) were subjected to rigorous database searches to 
identify potential confl  icting transcript matches to pseudogenes or homolo-
gous domains within related genes. Amplicons generated from the primer set 
were analyzed for melting point temperatures using the fi  rst  derivative 
primer melting curve software supplied by Applied BioSystems. The SYBR 
Green I assay and the ABI Prism 7500 Sequence Detection System (Applied 
Biosystems) were used for detecting real-time PCR products from the re-
verse-transcribed cDNA samples using a master template. PCR reactions for 
each sample were performed in triplicate, and copy numbers were measured 
as described previously (30). The level of target gene expression was normal-
ized against the 18S rRNA expression in each sample and, the data were 
presented as mRNA copies per 106 18S rRNA copies.
Immunohistochemistry. Immunohistochemistry was performed on 5-μm 
frozen sections from the heart, brain, and lung of control and LPS-treated 
mice. Antibodies included rabbit polyclonal anti–mouse P-selectin anti-
body (Chemicon International), rabbit polyclonal anti–mouse PAI-1 antibody 
(Innovative Research Inc.), rabbit polyclonal anti–mouse Cox-2 antibody 
(Cayman Chemical), rat monoclonal anti–mouse E-selectin antibody (BD 
Biosciences), rat monoclonal anti–mouse VCAM-1 antibody (Chemicon 
International), and rat monoclonal anti–mouse ICAM-1 antibody (Serotec 
Ltd). Anti–rat IgG antibody conjugated with FITC and anti–rabbit IgG anti-
body conjugated with Cy3 (Zymed Laboratories) were used as secondary 
  antibodies. For colocalization studies, a rat monoclonal anti–mouse CD31 
antibody (BD Biosciences) was used in double immunofl  uorescent stains with 
rabbit polyclonal antibodies (P-selectin, PAI-1, and Cox-2), and a rabbit 
polyclonal anti–mouse vWF antibody (Abcam Inc.) was combined with the 
rat monoclonal anti–mouse antibodies (E-selectin, VCAM-1, and ICAM-1).
Cell culture. HUVECs were cultured in EGM medium (Cambrex Bio 
  Science). Once cells reached 70% confl  uence, they were serum starved in 
0.5% FBS EGM for 20 h and incubated with 0.1 ng/ml TNF-α, 100 ng/ml 
VEGF, and 200 ng/ml PlGF alone or in combination for 4 h. The cells were 
harvested for RNA and processed for mRNA expression as described in 
  Tissue RNA isolation…analysis.
Survival study. 3 d before LPS injection or CLP, C57BL/6 male mice 
were treated with the control (GFP), sFlt-1, PlGF, and/or VEGF-A adeno-
viruses. Alternatively, animals received the aforementioned anti–Flk-1 anti-
body, anti–Flt-1 antibody, or sFlt-1 peptide. Survival was assessed at 24, 48, 
72, and 96 h after 20-mg/kg weight LPS injection or CLP.
Statistical analysis. Student t test was used for statistical analysis in mouse 
cytokine and gene expression studies. Analysis of variance was used for sta-
tistical analysis of cardiac physiology data. General linear model repeated 
measures were used to assess diff  erences between human subject groups (pla-
cebo vs. endotoxin). The Greenhouse-Geisser correction of degrees of free-
dom was applied where appropriate. In cases of condition or interaction 
eff  ects, simple contrasts were used to specify which time points signifi  cantly 
diff  ered from each other. Survival data were analyzed by the construction of 
Kaplan-Meier plots and use of the log-rank test.
Online supplemental material. Table S1 shows VEGF and PlGF time 
course in a human model of endotoxemia. Table S2 shows the expression 
profi  le of genes involved in infl  ammation and coagulation in organs from 
control or LPS-treated mice. Table S3 describes baseline characteristics and 
the 28-d mortality rate of patients with severe sepsis. Table S4 provides the 
DNA sequences for the forward and reverse primers used in TaqMan analy-
ses. Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20060375/DC1.
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